Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05804916

Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer

A Single-center, Blinded, Efficacious, Phase III Randomized Clinical Trial Initiated by Investigators to Investigate the Use of Surface Guided Radiation Therapy (SGRT) in Combination With Deep Inspiration Breath Hold (DIBH) Technique for Left Breast Cancer Treatment, Compared to Traditional Laser Alignment With Free Breathing Treatment

Status
Recruiting
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
556 (estimated)
Sponsor
Peking Union Medical College Hospital · Academic / Other
Sex
Female
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study is a single-center,blinded, efficacious, phase III randomized clinical trial initiated by investigators. The primary objective is to investigate the use of Surface Guided Radiation Therapy (SGRT) in combination with Deep Inspiration Breath Hold (DIBH) technique for left breast cancer treatment, compared to traditional laser alignment with free breathing treatment. This approach offers superior positioning accuracy and improved heart protection without any increase in radiation or adverse reactions.

Detailed description

This is an investigator-initiated blinded, efficacious, phase III randomized clinical trial study. The study hypothesis is that the use of Surface Guided Radiation Therapy (SGRT) in combination with the Deep Inspiration Breath Hold (DIBH) technique for left breast cancer treatment can improve positioning accuracy and heart protection without any increase in radiation or adverse reactions. The primary endpoint of this study is the accuracy of the treatment location and incidence of patient coronary events/myocardial perfusion decline.

Conditions

Interventions

TypeNameDescription
DEVICESurface Guided Radiation Therapy (SGRT)SGRT and DIBH those two devices could be combined together to improve the accuracy in radiation therapy position and heart protection

Timeline

Start date
2022-04-01
Primary completion
2027-04-01
Completion
2027-04-01
First posted
2023-04-07
Last updated
2023-04-07

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05804916. Inclusion in this directory is not an endorsement.